HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

Benzinga Newsdesk www.benzinga.com Neutral 50.1%

Neg 0% Neu 50.1% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.